Stem cell therapy for retinitis pigmentosa aims to slow the loss of retinal function by supporting the cells that are still alive, rather than replacing the entire retina. It remains an area of active clinical research, and results differ from person to person, so an honest discussion of the rationale and the limits comes before any decision.
For patients considering India, this page describes what the therapy is based on, which kinds of cells are generally discussed and how suitability is judged.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
If a patient is found suitable, the cells are processed under laboratory protocols and delivered by the route the retina specialist considers appropriate for that particular eye. Review visits at planned intervals then compare new test results with the baseline. The realistic aim is to slow or steady the course and, in some patients, to support modest functional gain. No outcome can be guaranteed.
“No. It is not a cure and it does not repair the underlying gene. The purpose is to support remaining retinal cells, and the response differs from one patient to another.”
”
Any procedure near the eye can carry risks such as infection, inflammation or bleeding. These are discussed in detail before consent so that patients can weigh benefits and risks for themselves.”
“People with very advanced disease and almost no remaining retinal function, uncontrolled general illness or an active eye infection may not be suitable. This is decided only after a full evaluation.”
“The plan for one eye or both is made by the treating specialist after reviewing test results and the patient’s goals.”
